Glenn McDermott, MD
Family Medicine · Virginia Beach, VANPI 1447261862
Payments from drug & device makers
Across 558 payments — averaging $32.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$6K
- AstraZeneca$3K
- Johnson & Johnson$2K
- Paratek Pharmaceuticals, Inc.$910
- Lilly USA, LLC$717
- AbbVie$631
- plus $5K from 24 others
What the payments were for
- Consulting fees$8004%
- Speaking & faculty fees$3,60020%
- Food & beverage$13,60875%
- Education$2201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 81 | $5,561 |
| AstraZeneca | 85 | $3,192 |
| Johnson & Johnson(2 entities) | 55 | $1,756 |
| Paratek Pharmaceuticals, Inc. | 8 | $910 |
| Lilly USA, LLC | 36 | $717 |
| AbbVie(2 entities) | 37 | $631 |
| Amarin Pharma, Inc. | 32 | $626 |
| Boehringer Ingelheim | 25 | $560 |
| GSK | 28 | $520 |
| Novo Nordisk | 17 | $459 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 32 | $453 |
| Novartis | 26 | $426 |
| Pfizer | 25 | $371 |
| Biohaven Pharmaceuticals, Inc. | 12 | $334 |
| Boston Scientific | 9 | $304 |
| Galderma Laboratories, L.p. | 9 | $209 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $207 |
| Astellas Pharma US Inc | 3 | $199 |
| Merck | 9 | $141 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $134 |
| Eisai Inc. | 1 | $125 |
| Tactile Systems Technology Inc | 1 | $105 |
| Esperion Therapeutics, Inc. | 3 | $77 |
| Kowa Pharmaceuticals America, Inc. | 5 | $66 |
| Hikma Pharmaceuticals USA | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Genentech USA, Inc. | 2 | $27 |
| Assertio Therapeutics, Inc. | 1 | $16 |
| Cashflow Solutions, LLC | 1 | $16 |
| Zyla Life Sciences, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,228 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 51 | $48,274 |
| JardianceEmpagliflozin | 23 | $37,329 |
| MounjaroTirzepatide | 15 | $32,884 |
| JanuviaSitagliptin Phosphate | 30 | $32,474 |
| FarxigaDapagliflozin Propanediol | 21 | $27,195 |
| EliquisApixaban | 24 | $27,120 |
| TrulicityDulaglutide | 14 | $22,849 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $10,453 |
| Praluent PenAlirocumab | 11 | $5,196 |
| Potassium Chloride | 39 | $2,611 |
| Rosuvastatin Calcium | 118 | $1,804 |
| Atorvastatin Calcium | 150 | $1,391 |
| Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril | 52 | $978 |
| Nebivolol Hcl | 22 | $945 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $725 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $717 | $55,73229 claims |
| Johnson & JohnsonXarelto | $1,756 | $48,27451 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $3,192 | $37,64839 claims |
| Boehringer IngelheimJardiance | $560 | $37,32923 claims |
| MerckJanuvia | $141 | $32,47430 claims |
| PfizerEliquis | $371 | $27,12024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Virginia Beach
- Gregory HaaseVirginia Beach$517K
- Ted KubickiVirginia Beach$159K
- Jim-David GaglioneVirginia Beach$24K
- Michael CharlesVirginia Beach$18K
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
- Linda SchneiderHampton$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.